There were 1,843 press releases posted in the last 24 hours and 442,588 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image